Analyst firms · Morgan Stanley · EVO
Morgan Stanley EVO price target and rating history
Evotec SE (EVO) · Health Care
Morgan Stanley rates Evotec SE (EVO) Equal-Weight with a $6 price target, as of its latest action on Jul 29, 2024. It has published 4 rating actions on EVO since August 2022, including 2 upgrades and 2 downgrades.
- Current rating
- Equal-Weight
- Price target
- $6
- Median target, all firms
- Too few
- Actions on EVO
- 4
Morgan Stanley price target on EVO
Every Morgan Stanley rating on EVO
- Jul 29, 2024
- Jun 23, 2023
- Apr 4, 2023
- Aug 10, 2022
How other firms rate EVO
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Berenberg | Hold | Jul 16, 2026 | |
| TD Cowen | Hold | $2 | Jul 15, 2026 |
| H.C. Wainwright | Buy | $7 | Apr 15, 2026 |
Questions about Morgan Stanley and EVO
- What is Morgan Stanley's price target for EVO?
- Morgan Stanley's latest stated price target for Evotec SE (EVO) is $6, from its action on Jul 29, 2024.
- What is Morgan Stanley's rating on EVO?
- Morgan Stanley rates EVO Equal-Weight, a neutral rating, as of Jul 29, 2024.
- When did Morgan Stanley last change its view on EVO?
- On Jul 29, 2024, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $15 to $6.
More EVO rating histories
All Morgan Stanley ratingsEVO news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.